Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
AR101 Real-World Open-Label Extension Study
NCT03337542 · View on ClinicalTrials.gov ↗
Study Summary
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
Conditions Studied
Interventions
- BIOLOGICAL AR101
Study Locations (20)
California
- Jonathan Corren, M.D., Inc. — Los Angeles
- Allergy & Asthma Associates of Southern California — Mission Viejo
- Sean N. Parker Center for Allergy Research at Stanford University - Packard-El Camino Hospital — Mountain View
- Peninsula Research Associates — Rolling Hills Estates
- Allergy & Asthma Medical Group and Research Center — San Diego
- Rady Children's Hospital, Div. Allergy & Immunology, UC San Diego — San Diego
- UCSF, Benioff Children's Hospital - Allergy and Immunology — San Francisco
- Allergy & Asthma Associates of Santa Clara Valley Research Center — San Jose
- UCLA Medical Center, Santa Monica — Santa Monica
- Bay Area Allergy — Walnut Creek
Colorado
- Children's Hospital Colorado — Aurora
- Asthma & Allergy Associates — Colorado Springs
- National Jewish Health — Denver
- Colorado Allergy & Asthma Centers, P.C. — Denver
Arizona
- Medical Research of Arizona — Scottsdale
- Banner University of Arizona Medical Center — Tucson
Alabama
- Clinical Research Center of Alabama — Birmingham
Arkansas
- Arkansas Children's Hospital — Little Rock
District of Columbia
- Children's National Medical Center — Washington D.C.
Florida
- Sher Allergy Specialists - Center for Cough — Largo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03337542
The ClinicalTrials.gov registry entry for NCT03337542 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aimmune Therapeutics, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 1 intervention — of which AR101 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03337542 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Colorado, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03337542 about?
NCT03337542 is a clinical study titled "AR101 Real-World Open-Label Extension Study". This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
What is the current status of trial NCT03337542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 243 participants. The study started on 2017-10-18. Estimated completion is 2019-09-20.
What conditions does trial NCT03337542 study?
This clinical trial studies the following conditions: Peanut Allergy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03337542?
The interventions under investigation include: AR101 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03337542?
This trial is sponsored by Aimmune Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03337542 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.